Paxman

47.00 SEK

+0.43 %

Less than 1K followers

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+0.43 %

-1.05 %

-16.37 %

-14.55 %

-36.83 %

-22.70 %

+30.56 %

+16.63 %

+331.19 %

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Market cap

1.09B SEK

Turnover

499.6K SEK

Revenue

313.35M

EBIT %

1.36 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

21/5

2026

Interim report Q1'26

22/5

2026

General meeting '26

21/8

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Press release3/2/2026, 10:19 AM

Redeye: Paxman (Q4 Review): Quarter below expectations, but IBBM development is encouraging

Press release3/2/2026, 7:42 AM

DNB Carnegie Access: Paxman: Closing the chapter on an eventful 2026 – Q4 review

Press release2/27/2026, 7:49 AM

DNB Carnegie Access: Paxman: Margin pressure reached its peak – Q4 initial comment

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release2/27/2026, 6:00 AM

PAXMAN publishes year-end report as of 31 December 2025.

Regulatory press release2/27/2026, 6:00 AM

PAXMAN publishes year-end report as of 31 December 2025

Press release2/23/2026, 10:30 AM

Inbjudan: Livesänd presentation med Richard Paxman – Bokslutskommuniké 2025

Press release2/23/2026, 10:30 AM

Invitation: Live Presentation with CEO Richard Paxman – Year-end report 2025

Press release2/23/2026, 9:53 AM

DNB Carnegie Access: Paxman: Category III CPT Codes for Cryocompression secured

Press release2/23/2026, 9:13 AM

Redeye: Paxman: CPT-III codes for Paxman’s CIPN device

Press release2/20/2026, 3:17 PM

Paxman tillkännager kategori III CPT-koder för kryokompressionsterapi för att förebygga kemoterapiinducerad perifer neuropati

Press release2/20/2026, 3:17 PM

Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral Neuropathy

Press release2/2/2026, 5:23 PM

DNB Carnegie Access: Paxman: FX pressure but growth drivers are intact – Q4 preview

Press release12/31/2025, 12:50 PM

PAXMAN meddelar att bolaget har lämnat in en 510(k)-ansökan till FDA för sin kryokompressionsenhet för förebyggande av kemoterapiinducerad perifer neuropati (CIPN).

Press release12/31/2025, 12:50 PM

PAXMAN announces 510k Submission to the U.S. Food and Drug Administration (FDA) for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Press release11/27/2025, 4:59 PM

DNB Carnegie Access: Paxman: Key highlights from Capital Markets Day

Press release11/24/2025, 6:45 PM

Rättelse: Ytterligare uppdaterade uppgifter om ersättning för OPPS

Press release11/24/2025, 6:45 PM

Correction: Further updated Information on OPPS Reimbursement

Press release11/24/2025, 5:41 PM

Rättelse: Uppdaterade uppgifter om ersättning för OPPS

Press release11/24/2025, 5:41 PM

Correction: Updated Information on OPPS Reimbursement

Press release11/24/2025, 5:00 PM

DNB Carnegie Access: Paxman: CMS Final Rule landed neutral – long-term story intact

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.